Los Angeles Capital Management & Equity Research Inc. cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,840 shares of the company’s stock after selling 178 shares during the period. Los Angeles Capital Management & Equity Research Inc.’s holdings in IDEXX Laboratories were worth $546,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ameriprise Financial Inc. raised its position in IDEXX Laboratories by 10.7% in the third quarter. Ameriprise Financial Inc. now owns 588,789 shares of the company’s stock worth $66,369,000 after buying an additional 56,960 shares in the last quarter. Stevens Capital Management LP bought a new position in IDEXX Laboratories during the third quarter worth $1,329,000. Municipal Employees Retirement System of Michigan raised its position in IDEXX Laboratories by 1.4% in the third quarter. Municipal Employees Retirement System of Michigan now owns 40,190 shares of the company’s stock worth $4,531,000 after buying an additional 540 shares in the last quarter. Tower Research Capital LLC TRC raised its position in IDEXX Laboratories by 17.6% in the third quarter. Tower Research Capital LLC TRC now owns 3,196 shares of the company’s stock worth $360,000 after buying an additional 479 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in IDEXX Laboratories by 185.1% in the third quarter. Canada Pension Plan Investment Board now owns 185,612 shares of the company’s stock worth $20,924,000 after buying an additional 120,512 shares in the last quarter. Institutional investors own 90.74% of the company’s stock.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded down 0.92% during mid-day trading on Wednesday, reaching $118.90. The company had a trading volume of 730,228 shares. The company has a 50 day moving average price of $118.47 and a 200 day moving average price of $110.59. IDEXX Laboratories, Inc. has a one year low of $63.48 and a one year high of $121.81. The company has a market capitalization of $10.66 billion, a price-to-earnings ratio of 50.64 and a beta of 0.51.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. IDEXX Laboratories had a negative return on equity of 788.91% and a net margin of 12.36%. The firm had revenue of $448.30 million for the quarter, compared to the consensus estimate of $448.60 million. During the same quarter in the prior year, the business earned $0.48 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts anticipate that IDEXX Laboratories, Inc. will post $2.38 EPS for the current year.
A number of research analysts have recently weighed in on the company. Zacks Investment Research lowered IDEXX Laboratories from a “hold” rating to a “sell” rating in a report on Monday. Canaccord Genuity set a $125.00 target price on IDEXX Laboratories and gave the company a “buy” rating in a report on Saturday, October 15th. Finally, Bank of America Corporation restated a “neutral” rating on shares of IDEXX Laboratories in a report on Thursday, September 29th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $105.20.
In related news, Chairman Jonathan W. Ayers sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $107.85, for a total value of $4,314,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas Craig sold 8,500 shares of the company’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $120.06, for a total value of $1,020,510.00. Following the completion of the sale, the director now owns 32,783 shares in the company, valued at approximately $3,935,926.98. The disclosure for this sale can be found here. Company insiders own 2.79% of the company’s stock.
IDEXX Laboratories Company Profile
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).